Treatment of Depression Following Multiple Brain Tests

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-12-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to correlate brain testing with treatment outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

NCT01541475

Major Depressive Disorder

COMPLETED PHASE4

Are Two Antidepressants a Good Initial Treatment for Depression?

NCT00296712

Major Depression Dysthymia Depression NOS

COMPLETED PHASE4

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755

Major Depressive Disorder Dysthymia

COMPLETED PHASE4

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

NCT00456014

Depression

COMPLETED NA

Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

NCT03278938

Depressive Illness

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

40 medication-free Depressed Patients will receive a battery of neuropsychologic tests, standard dichotic listening tests, EEG, ERP and an f-MRI while performing a neuropsychologic test, the Simon. Once testing is completed, patients will be treated in an open treatment trial of SSRI. Non-responders will then receive Bupropion followed by Tricyclic Antidepressant if still depressed. While our main purpose is to correlate imaging testing with other measures of brain functioning, we also intend to see whether f-MRI findings demonstrate specific brain areas which differ between responders and non-responders. At the end of SSRI treatment, patients will have a second f-MRI scan to investigate any changes treatment and/or response may have caused.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depression Dysthymia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

escitalopram

escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

8 weeks: up to 40 mg/day

bupropion

bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d

Group Type EXPERIMENTAL

Bupropion

Intervention Type DRUG

8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.

imipramine

imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted

Group Type EXPERIMENTAL

Imipramine

Intervention Type DRUG

8 weeks: up to 300mg/day

\*if patient does not have contraindication.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

8 weeks: up to 40 mg/day

Intervention Type DRUG

Bupropion

8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.

Intervention Type DRUG

Imipramine

8 weeks: up to 300mg/day

\*if patient does not have contraindication.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro Wellbutrin Tofranil, Pressamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-IV Major Depression or Dysthymia
* Age 18-65
* Physically healthy
* Normal hearing
* Drug-free (two weeks for most antidepressants, four weeks for Fluoxetine)

Exclusion Criteria

* Hearing deficit in one or both ears
* Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
* History of Psychosis or Epilepsy
* Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
* Unstable medical problem
* Insufficient English for neuropsychological and dichotic testing
* Bipolar I
* Need for wash-out from effective treatment in order to participate
* Pregnant
* High suicide risk
* Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No